This move is archived. Current quotes and coverage live on the stock page.
Get CRDL alerts:
Cardiol Therapeutics Inc Class A is experiencing a notable decline, with shares down 2.65% in the last trading session.
In a challenging trading day for Cardiol Therapeutics Inc Class A (CRDL.TO), the stock fell by 2.65%, closing at CA$1.47. This drop reflects investor sentiment amid a lack of significant news to boost confidence in the stock.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$321.26M
52W high
$3.15
52W low
$1.23
1W change
+9.78%
Beta
0.47
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 98.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+98.0% Upside
Current Price
C$3.03
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
72.1%
Annualized
90-Day Vol
57.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$3.62
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$3.22 | C$2.51 โ C$4.12 |
| 60 trading days | C$3.41 | C$2.40 โ C$4.85 |
| 90 trading days | C$3.62 | C$2.35 โ C$5.57 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should remain cautious as Cardiol Therapeutics navigates a volatile market without recent positive catalysts to support its share price.
CRDL.TO down 2.65% in last session
The stock's market cap stands at CA$174 million, indicating its small-cap status and the inherent volatility that comes with it.
Bull case
If Cardiol Therapeutics can effectively leverage its ongoing clinical trials and expand its market presence, thereโs potential for recovery and growth in the long term.
Bear case
Without immediate positive developments or news, the stock may continue to face pressure, especially in a market sensitive to biotech performance.
Market Performance Overview
Advertisement
Cardiol Therapeutics Inc Class A shares fell by 2.65% in the last trading session, reflecting broader market trends that often affect small-cap biotech stocks. With a current market cap of CA$174 million, the stock's movements are particularly sensitive to investor sentiment and market conditions.
Lack of Catalysts
Despite previous announcements regarding clinical trials and shareholder meetings, Cardiol Therapeutics has not released any recent news to support a bullish outlook. Investors may hesitate to buy in the absence of positive developments, contributing to the stock's decline.
Looking Ahead
As Cardiol Therapeutics continues to navigate the complexities of the biotech industry, investors should keep an eye on upcoming announcements. The potential for recovery depends on the company's ability to generate positive news and results from its ongoing clinical trials.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
